A Study to Learn About a Vaccine Against E Coli in Healthy Adults
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY-UNBLINDED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE AGAINST E COLI IN HEALTHY ADULTS
Pfizer
310 participants
Aug 11, 2025
INTERVENTIONAL
Conditions
Summary
This study evaluates an investigational vaccine designed to protect against Escherichia coli (E coli). The primary objective is to assess the safety and tolerability of E coli vaccines administered intramuscularly to healthy adults.
Eligibility
Inclusion Criteria3
- Ages Eligible for Study: 18 to 64 Years (Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes
- Adult Participants >= 18 through < 64 years of age at the time of enrollment.
- Healthy participants as determined by medical history, physical examination, and clinical judgement of the investigator to be eligible for inclusion in the study.
Exclusion Criteria3
- Severe adverse reaction history associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).
- Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
- Women who are pregnant, plan to become pregnant during the study, or are breastfeeding.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Candidate E coli vaccine 1 Dose A, administered according to a 0, 6-month interval
Candidate E coli vaccine 1 Dose B, administered according to a 0, 6-month interval
Candidate E coli vaccine 2, administered according to a 0, 6-month interval
Candidate E coli vaccine 3, administered according to a 0, 6-month interval
Candidate E coli vaccine 4 Dose A, administered according to a 0, 6-month interval
Candidate E coli vaccine 4 Dose B, administered according to a 0, 6-month interval
Candidate E coli vaccine 4 Dose C, administered according to a 0, 6-month interval
Candidate E coli vaccine 5 Dose A, administered according to a 0, 6-month interval
Candidate E coli vaccine 5 Dose B, administered according to a 0, 6-month interval
Placebo administered according to a 0, 6-month interval
Locations(11)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07122986